Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NEPHthis companyNephros, Inc.	$3.08	44.36×	5.08×	2.76×	35.25×	-265.9%	61.1%	6.1%	6.4%	11.7%	10.1%	3.2%	0.1×	-3.22×	1,146×	4.06×	0.0%	4	-4.58	3	B
BEATHeartBeam, Inc.	$0.40	-3.87×	31.08×	0×	-3.65×	-74.8%	0.0%	0.0%	0.0%	-807.3%	-812.1%	-18.0%	0×	0.21×	0×	1.45×	0.0%	2	-11.41	1	C-
DXRDaxor Corporation	$8.40	8.02×	1.6×	146.07×	8.02×	-100.3%	37.5%	1824.7%	1821.5%	20.0%	20.0%	-0.8%	0×	0.01×	575.44×	0×	0.0%	3	1,336.57	3	B+
HOWLWerewolf Therapeutics, Inc.	$1.05	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
ICCCImmuCell Corporation	$10.18	-51.25×	2.05×	2.01×	30.32×	-213.6%	41.4%	6.0%	-3.8%	-3.8%	4.1%	2.2%	0.49×	4.39×	3.76×	4.26×	0.0%	7	4.6	2	C
NRXPNRx Pharmaceuticals, Inc.	$2.42	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
Peer median	—	-2.02×	1.6×	2.01×	0.36×	-74.8%	37.5%	0.0%	0.0%	-3.8%	4.1%	-18.0%	0×	0.26×	0×	1.45×	0.0%	4	-11.41	2	—